Durable response to dual immune checkpoint blockade in Lynch syndrome-associated serous ovarian carcinoma: a case report. (PubMed, Front Med (Lausanne)) - Sep 17, 2026 - "Following multidisciplinary discussion, combined chemoimmunotherapy was recommended; however, the patient declined cytotoxic chemotherapy and was treated with dual immune checkpoint blockade (ipilimumab and nivolumab)...Maintenance nivolumab and bevacizumab were initiated postoperatively...Despite the serous histology of the patient's ovarian cancer, the presence of dMMR by immunohistochemistry and an underlying history of Lynch syndrome supported the use of a chemotherapy-free regimen with dual ICIs. Subsequent somatic next-generation sequencing revealed MSI-H/TMB-H disease, which explains the remarkable response that the patient had."
Checkpoint inhibition • IO biomarker • Journal • Tumor mutational burden • Genetic Disorders • High Grade Serous Ovarian Cancer • Microsatellite Instability • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • MSH2 • MSI • TMB
|
|
Ali Shamseddine; Layal Al Mahmasani; Mohamad Mourad; Nada Assaf; Najla Fakhruddin; Rami Mahfouz
|